RB1 and prostate carcinoma: Again, E1A/E1B double mutant oncolytic adenovirus is able to replicate in targeted cells and lyse tumor cells that have abnormalities in p53 and/or p16/Rb/E2F pathways.[19] Prostate cancer often has a wide range of genetic mutations, including the p53, pRb, and p16 pathways,[28] and would be an ideal organ site for oncolytic adenovirus therapy.